Hims & Hers Health, a leading digital healthcare company, has seen significant success in 2025, with triple-digit growth and a market cap of $11 billion. Despite this, CEO Andrew Dudum’s recent $11 million stock sale has caused shares to drop over 10%, sparking concerns among investors about the company’s future. Hims & Hers is expanding its offerings, including a new Menopause and Perimenopause specialty within its “Hers” division, aiming to reach over $1 billion in revenue by 2026. The company’s Q2 2025 results showed strong growth, with revenue up 73% year-over-year and an increase in subscribers to over 2.4 million. Analysts are divided on the stock, with a consensus rating of “Hold” and a price target suggesting potential 70% growth. CEO Dudum’s stock sale has raised questions about the company’s trajectory, but Hims & Hers remains focused on growth and innovation in the digital healthcare space.

Read more at Yahoo Finance: CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You?